Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myconostica launches "improved" Pneumocystis test in the EU and Canada

This article was originally published in Clinica

Executive Summary

Myconostica has launched a new version of its MycAssay Pneumocystis test in Europe and Canada. The test detects the fungus Pneumocystis jirovecii, a major cause of pneumonia in immunocompromised people, including HIV/AIDS patients. It can provide results in three hours when combined with the firm's MycXtra fungal DNA extraction system, to help select appropriate drugs and improve patient outcomes. Manchester, UK-based Myconostica originally launched the real-time PCR test outside the US in April 2009. It says that the new version has "improved clinical performance and increased analytical sensitivity". Meanwhile, the company has signed a deal with Bactus (Huddinge, Sweden), making the latter the exclusive distributor of Myconostica's products in Sweden and Finland.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel